I have been wondering why we dropped imyc as a target because it was supposedly going to take a long and expensive road to get it to the stage of meaningfull trials. No, we are going to pivot to being a platform.
Yet almost within weeks we are now chasing a new target or targets?? Surely that just contradicts the "pivot to platform" we just did? If we were truly pivoting to platform surely it would all be about 40x or 100x tat penetration cpp and hoping a partner appears?
I personally am hoping the selection of the new target came about because someone showed serious interest and indicated there was possibly a significant commercial outcome if we could achiece certain goals?? Otherwise i dont fully understabd but if we didnt have some serious third party interest in these new targets then why pick then after we just dropped imyc?. If yhere was no third party interest are these targets quicker or easier to clinic i wonder?
From Hottods post "Phylogica has a near-term opportunity to improve the commercial attractiveness of our platform by showing that we can deliver a cargo class of interest into a target cell of interest more efficiently than the relevant competitive technology. The outcome of these comparative studies and progression into clinical evaluation are the two primary drivers of platform validation and therefore the value of the company’s assets."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)